A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
Expanded access is no longer available for this treatment.
Information provided by:
Millennium Pharmaceuticals, Inc.
First received: July 7, 2003
Last updated: February 13, 2007
Last verified: July 2003
The purpose of this study is to give patients who have had 4 or more prior lines of therapy for multiple myeloma access to VELCADE. The study is for patients who are not eligible for other clinical trials with VELCADE and for who VELCADE would otherwise not be available.
What is Expanded Access?
||An Open-Labeled, Randomized Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE in Patients With Relapsed Multiple Myeloma Who Have Failed Four or More Lines of Therapy
| Estimated Enrollment:
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Plasmacytomas on tissue biopsy
- Bone marrow plasmacytosis (> 30% plasma cells)
- Monoclonal IgG is > 3.5 g/dL or IgA is > 2.0 g/dL; kappa or lambda light chain excretion is > 1 g/day on a 24 hour urine sample.
- Bone marrow plasmacytosis (10 to 30%)
- Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria.
- Lytic bone lesions
Other Eligibility Requirements:
- Patient is not eligible for Millennium Study M34101-039.
- Patient has received 4 or more lines of therapy for multiple myeloma and, in the investigator's opinion, currently needs therapy because of relapsed or progressive disease.
- Patient is of legal consenting age, as defined by local regulations.
- Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.
- Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care.
- Female patients must be either post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control throughout the study.
- Male patients must agree to use an acceptable method of birth control throughout the study.
- Patient has a Karnofsky performance status of greater than or equal to 60%.
- Patient meets pretreatment laboratory criteria at and within 14 to 21 days before Baseline (Day 1 of Cycle 1, before study drug administration).
- Patient progressed while receiving VELCADE previously in a clinical trial.
- Patient has been treated in Millennium Study M34101-039.
- Patient received corticosteroids (> 10 mg/day prednisone or equivalent) within 1 week before enrollment in the study.
- Patient received nitrosoureas within 6 weeks or any other chemotherapy within 3 weeks before enrollment in the study.
- Patient received immunotherapy or antibody therapy within 4 weeks before enrollment.
- Patient had major surgery with 4 weeks before enrollment (kyphoplasty isn't considered major surgery).
- Patient has a history of allergic reactions due to compounds containing boron or mannitol.
- Patient has peripheral neuropathy of Grade 2 or greater, as defined by the National Cancer Institute Common Toxicity Criteria (NCI CTC).
- Patient has a myocardial infarction within 6 months of enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias or electrocardiogram shows evidence of acute ischemia or active conduction system abnormalities.
- Patient has cardiac amyloidosis
- Patient has poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment.
- Patient is known to be infected with human immunodeficiency virus (HIV positive).
- Patient is known to be hepatitis B positive or has active hepatitis C infection.
- Patient has an active systemic infection requiring treatment.
- Female patient is pregnant or breast-feeding. Confirmation that the patient is not pregnant is required. Pregnancy testing is not required for post-menopausal or surgically sterilized patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00063791
|Michael Meshad, Oncology Center
|Mobile, Alabama, United States, 36608 |
|Henry Ford Health System
|Detroit, Michigan, United States, 48202 |
|Toledo, Ohio, United States, 43623 |
Millennium Pharmaceuticals, Inc.
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 7, 2003
||February 13, 2007
||United States: Food and Drug Administration
Keywords provided by Millennium Pharmaceuticals, Inc.:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 03, 2013
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Blood Protein Disorders
Immune System Diseases
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents